Recordati Q1 2026 net income rises 22.4% to € 153.1 million; revenue climbs 4.9% to € 713.4 million

  • Recordati Q1 2026 net revenue rose 4.9% to € 713.4 million, EBITDA increased 5% to € 283.6 million.
  • Adjusted net income climbed 7.2% to € 188.1 million, net income jumped 22.4% to € 153.1 million.
  • Free cash flow fell to € 92.1 million, down € 66.7 million, net debt stood at € 1.99 billion.
  • Rare Diseases revenue rose 14.8% to € 292.4 million, Specialty & Primary Care revenue slipped 1% to € 404.4 million.
  • FY 2026 targets were confirmed, with net revenue seen at € 2.73 billion-€ 2.8 billion; CEO Rob Koremans cited strong momentum in Rare Diseases and resilient in-market growth in the promoted Specialty & Primary Care portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.